TOP TEN perturbations for 39427_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39427_at
Selected probe(set): 205849_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39427_at (205849_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) / scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose)
Relative Expression (log2-ratio):3.191082Number of Samples:4 / 4
| Experimental | scleroderma study 8 (blood; anifrolumab; 1mg/kg/wk; multiple dose; 56d) |
| Whole blood samples collected from adult systemic sclerosis patients at day 56 after a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. ATC code:--- | |
| Control | scleroderma study 8 (blood; baseline; 1mg/kg/wk; multiple dose) |
| Whole blood samples from adult systemic sclerosis patients before a 4-week repeated intravenous injection of anifrolumab (1 mg/kg per week). Anifrolumab (MEDI-546) is a human IgG1κ mAb directed against subunit 1 of the type I IFN receptor. The patients were enrolled in a Phase 1 open-label clinical trial (study MI-CP180; NCT00930683). Further patient characteristics: Mean age (y): 49.3 ± 9.5; Mean weight (kg): 75.9 ± 33.7; Mean modified Rodnan Skin Score (mRSS): 24.5 ± 10.1. |
interferon-alpha-kinoid study 1 (30ug; 112d) / untreated whole blood sample
Relative Expression (log2-ratio):2.890623Number of Samples:3 / 43
| Experimental | interferon-alpha-kinoid study 1 (30ug; 112d) |
| Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 30ug INK-K at day 0, 7 and 58. Sample was taken 112 days after the first application of TNF-K. ATC code:--- | |
| Control | untreated whole blood sample |
| Whole blood samples from healthy volunteers. |
septic shock study 3 (D1; non-survivor) / normal blood sample
Relative Expression (log2-ratio):2.7554407Number of Samples:17 / 22
| Experimental | septic shock study 3 (D1; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
septic shock study 3 (D2; non-survivor) / normal blood sample
Relative Expression (log2-ratio):2.6636086Number of Samples:8 / 22
| Experimental | septic shock study 3 (D2; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
interferon-alpha-kinoid study 2 (240ug; 168d) / placebo treated whole blood sample
Relative Expression (log2-ratio):-2.6274166Number of Samples:3 / 6
| Experimental | interferon-alpha-kinoid study 2 (240ug; 168d) |
| Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 4 doses of 240ug INK-K at day 0, 7, 58 and 84. Sample was taken 168 days after the first application of TNF-K. ATC code:--- | |
| Control | placebo treated whole blood sample |
| Whole blood samples of patients with systemic lupus erythematosus after treatment with placebo (0.9% NaCl; hemocyanin as carrier). Patients had 3 doses at day 0, 7 and 58. Sample was taken 168 days after the first application of TNF-K. |
sarcoidosis study 4 / interstitial lung disease study 5 (HP)
Relative Expression (log2-ratio):2.6129951Number of Samples:38 / 6
| Experimental | sarcoidosis study 4 |
| Peripheral blood mononuclear cells (PBMC´s) obtained from patients with pulmonary sarcoidosis. Exclusion criteria were other concurrent systemic inflammatory conditions. Sarcoidosis was diagnosed according to established criteria (Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (Ers) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.AmJ Respir Crit CareMed 1999;160:736–755). | |
| Control | interstitial lung disease study 5 (HP) |
| Peripheral blood mononuclear cells (PBMC´s) obtained from patients with hypersensitive pneumonitis (HP). |
interstitial lung disease study 5 (HP) / normal PBMC sample
Relative Expression (log2-ratio):-2.5713654Number of Samples:6 / 20
| Experimental | interstitial lung disease study 5 (HP) |
| Peripheral blood mononuclear cells (PBMC´s) obtained from patients with hypersensitive pneumonitis (HP). | |
| Control | normal PBMC sample |
| Peripheral blood mononuclear cells (PBMC´s) derived from healthy controls. Control subjects had no lung disease or any other significant medical conditions. |
septic shock study 3 (D3; non-survivor) / normal blood sample
Relative Expression (log2-ratio):2.5506258Number of Samples:9 / 22
| Experimental | septic shock study 3 (D3; non-survivor) |
| Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
| Control | normal blood sample |
| Blood samples from healthy subjects. |
kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample
Relative Expression (log2-ratio):-2.5047417Number of Samples:3 / 3
| Experimental | kidney transplantation study 16 (2 week) |
| CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal natural killer cell (CD56+) sample |
| CD56+ natural killer cell samples derived from healthy control subjects. |
hypoxia study 7 (high altitude) / hypoxia study 7 (sea level)
Relative Expression (log2-ratio):2.4849253Number of Samples:96 / 98
| Experimental | hypoxia study 7 (high altitude) |
| Human peripheral monunuclear blood cells taken from the blood of healthy volunteers after acute elevation to high altitude at the South Pole McMurdo station on the third day. | |
| Control | hypoxia study 7 (sea level) |
| Human peripheral monunuclear blood cells taken from the blood of healthy volunteers at sea level at the South Pole McMurdo station on the third day. |